ADC Therapeutics SA (ADCT) Dividend History

ADC Therapeutics SA (ADCT) is a clinical-stage biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic and solid tumors. Founded in Switzerland, the company focuses on targeted cancer therapies designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissue. Its pipeline includes multiple ADCs in various stages of clinical development, aiming to address unmet medical needs in oncology.

Biopole, Epalinges, V8, 1066
Phone: 41 21 653 02 00
Website: https://www.adctherapeutics.com

Dividend History

ADC Therapeutics SA currently does not pay dividends

Company News

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.

Benzinga

Featured Companies: CTOR ONCY OSTX
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

GlobeNewswire Inc.

Featured Companies: ABBV ACLX BMY JNJ KROS MRK REGN SLS
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Page data last updated 07/23/2025 16:59:22 UTC